NSW companies dominate fourth-round BIF funding
01 May, 2003 by Pete YoungMore than 40 organisations -- nearly half of them in NSW -- will share nearly $AUD10 million from the fourth round of the federal government's Biotechnology Innnovation Fund (BIF) grants announced today.
Researchers explore biosensor applications for fluorescence discovery
28 April, 2003 by Melissa TrudingerA coral protein with an intense blue colour has properties that could prove useful as a biological probe to track interactions between proteins and cells, according to new research from Monash and Queensland universities.
Making IT headlines
28 April, 2003 by Eve EpsteinBob Palermini got his first taste of Unix some 25 years ago when he became involved in production at a small newspaper that used the system to set type. Although he started out as an editor, Palermini was hooked on IT after that initial experience and taught himself the skills to make the transition to the technology side of the business. “Early on it was trial and error and books,” he says.
The ones to watch
24 April, 2003 by Melissa TrudingerMelissa Trudinger takes a look at the emerging biotech clusters in Perth and Adelaide.
Value of deals overrated: KPMG
23 April, 2003 by Melissa TrudingerDoing deals is one of the cornerstones of biotechnology, and can cover a myriad of activities from obtaining private or public equity, to collaborations and joint ventures, and in- and out-licensing of technology and products. But while transactions can increase the value of a company, too often the deal itself can lead to a decline in shareholder value.
Eiffel wooed by US VC agents
22 April, 2003 by Jeremy TorrIn what it hopes is the first step towards a Nasdaq listing, Melbourne platform technology biotech Eiffel Technologies has appointed New York-based introduction agents Global Markets Capital Corporation (GMCC) to represent it on the US investor market.
Optiscan reveals tough new strategy
16 April, 2003 by Pete YoungListed biotech Optiscan Imaging, one of many struggling to conserve cash while waiting for their IP to reach commercial fruition, appears to have won some breathing space with a tough new strategy.
Opposition grows in face of PIIP axing rumours
16 April, 2003 by Jeremy TorrIndustry protests are coming loud and long following reports that the federal government's PIIP (Pharmaceutical Investment Incentive Scheme) may be axed in the next budget.
Euro-demand for Corbett range
15 April, 2003 by Jeremy TorrAustralian-based research instrument specialist Corbett Research has sealed a hardware deal with prime Swedish genetic analysis company Pyrosequencing.
VC: the smart money's in Australia, not the US
14 April, 2003 by Jeremy TorrA Sydney biotech conference has heard that the gold rush for venture capital in the US is becoming so constrained it makes sense to look at home.
Get familiar with new ASX rules, biotechs told
11 April, 2003 by Melissa TrudingerBiotechnology companies should make themselves aware of the new guidelines for corporate governance released by the ASX recently, says Chris Sotiropoulos, VP for commercialisation at Melbourne-based technology business development and commercialisation company Biocomm.
Seller beware: what do buyers of scientific equipment want?
10 April, 2003 by Melissa TrudingerKeeping up with the Joneses has become critical in research, where the race to achieve an important result not only guarantees a high-profile paper, but in the increasingly commercial world can provide an edge over a competing interest.
Circadian soars on buyback plan
10 April, 2003 by Melissa TrudingerIn a move that caused a 35 cent jump in the company's stock price, Melbourne firm Circadian announced yesterday that it would buy back up to 10 per cent of the company's outstanding shares.
CSIRO looking for growth in funding
04 April, 2003 by Simon GroseCSIRO chief executive Dr Geoff Garrett will have more riding on the May 13 Federal budget than most Australians. Halfway through his five-year appointment, he will be wanting to show his staff that they can look forward to real growth in public funding in the years ahead. If not, their disgruntlement over his challenging leadership may render the second half of his tenure more challenged than the first.
IBM, VPAC standardising bio-IT platform with $1m server
03 April, 2003 by David BraueThe amount of computing power available to Australian bioinformatics researchers continues to climb, with the Victorian Partnership for Advanced Computing (VPAC) this week switching on a massive $1 million clustered server from IBM that will more than double the organisation's computing power.
